Video
Martin Barrett on Intravenous Versus Subcutaneous Rituximab
Author(s):
Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
In this study, the standard dose of IV rituximab was concentrated 12 fold, to 120 mg/ml and mixed with a naturally occurring enzyme which allows it to be injected at volumes that would otherwise be difficult to administer, says Barrett.
The injection takes only six minutes, compared with a two to four hour infusion. Complete and overall response rates and toxicity were comparable between the two administration methods.
<<<
View more from the 13th International Conference on Malignant Lymphoma
